Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Signaturefd LLC

Signaturefd LLC raised its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 6,550.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,650 shares of the company’s stock after acquiring an additional 6,550 shares during the quarter. Signaturefd LLC’s holdings in Structure Therapeutics were worth $138,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Cubist Systematic Strategies LLC grew its stake in Structure Therapeutics by 3,326.0% in the first quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company’s stock worth $949,000 after purchasing an additional 53,216 shares in the last quarter. GAMMA Investing LLC grew its stake in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock worth $152,000 after purchasing an additional 7,627 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Structure Therapeutics by 58.6% in the second quarter. Exchange Traded Concepts LLC now owns 61,732 shares of the company’s stock worth $1,280,000 after purchasing an additional 22,809 shares in the last quarter. Parallel Advisors LLC acquired a new position in Structure Therapeutics in the second quarter worth about $171,000. Finally, Trexquant Investment LP grew its stake in Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company’s stock worth $2,083,000 after purchasing an additional 67,464 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $27.28 on Friday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $43.46. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -25.98 and a beta of -1.65. The firm’s 50 day moving average price is $20.61 and its two-hundred day moving average price is $20.96.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Guggenheim cut their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Saturday, September 27th. HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Finally, JMP Securities cut their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $68.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.